Introduction
It was reported in a recent review that 5400 new molecule entities were in the clinical research process in 2013 [1] . Research on rare diseases is one of the fastest growing areas in medicine in recent years. A total of 1795 projects about rare diseases were reported as being in the development process [1] . This research may increase in the coming years. A substantial part of the research on orphan drugs for rare diseases is led by small pharmaceutical and biotechnology companies because such drugs are potentially easier to get onto the market than are drugs are intended to treat widespread diseases and conditions. This is due to several reasons-for example, the well-known etiology, hence the clinical interest and expertise to treat common diseases, and the fact that common drugs are launched at much lower prices than are orphan drugs. Orphan drugs are intended to be used in a country or region in the same way as regular medications (e.g., antihypertension medications). Although there is high demand for orphan medications for specific diseases, it is much more difficult to design clinical research for orphan drugs than for other drugs because of low numbers of the target patient population.
Rare diseases are defined in the United States as diseases or conditions affecting fewer than 200,000 individuals [2, 3] . The European Union (EU) defines rare diseases as life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people [4] [5] [6] . Definitions of orphan drugs are used for classifying medicinal products intended to treat rare diseases.
The Orphan Drug Act of 1983 defined a pathway through new product development: with data supporting the treatment of a rare disease or condition, a medicine can receive orphan designation status in the United States [7] [8] [9] . The EU implemented regional policies in 2000 with the aim of improving research and development in the field of orphan drugs [4, 5, 10] . According to one study, an application for an orphan status designation from the US Food and Drug Administration (FDA) is perhaps the simplest and most straightforward request that can be made to the FDA [8] .
Although the cost of launching orphan drugs for rare diseases is similar to that of launching drugs for common diseases, the low patient numbers increase the price of orphan drugs. Because of the inverse proportion between patient numbers and prices, no alternative health technology exists for many orphan drugs [5] . This is, of course, one bottleneck in the course of orphan drug development. To manage this situation, many countries and regions around the world offer economic incentives to make orphan drug development attractive, especially to small and medium companies [11] [12] [13] .
The cost of most orphan drugs is higher than that of conventional drugs. In addition, the lack of clinical data on orphan drugs restricts pharmacoeconomic assessments. Both make reimbursement difficult. The first-line approach to aid reimbursement decision making on orphan drugs is to conduct additional assessments after the enactment of orphan drug legislation [14] .
One hundred twelve different active substances are listed as orphan drugs by Orphanet [15] . The FDA and the European Medicines Agency (EMA) have already classified a number of rare diseases and orphan drugs, with the EMA authorizing 60 different orphan drugs to date [16, 17] . Although there is no official definition of orphan drugs in Turkey, a working group has been established and is used in establishing laws and definitions related to rare diseases.
The [18] (Fig. 1) . Orphan drugs are exempted from this requirement. In accordance with the Notification on the Pricing of Medicines, the TITCK sets the price of these drugs using the reference prices, as documented by the official records of the country of manufacture or export (this is considered to be the original price). The SGK reviews orphan drug prices annually and revises them on the basis of their sales volume. All orphan drugs entering the market are reimbursed without any co-payment. Because the TITCK does not have to present a pharmacoeconomic analysis to the SGK for reimbursement decisions of orphan drugs, such drugs may enter the market faster than conventional drugs [19] .
However, most of the orphan drugs accessed in the country, which are not licensed by the TITCK, may be in the hands of the responsible physician and the patient in need with the early access procedure defined by the TITCK. This procedure allows physicians to prescribe off-label medications or unlicensed drugs. 
physician who wants to prescribe an off-label or unlicensed pharmaceutical is obliged to apply to the TITCK for named patient approval. The TITCK then evaluates each application on the basis of published scientific evidence and the advice of scientific committees. When the TITCK approves the use of an off-label or unlicensed medicine, the Turkish Pharmacists' Association-Türk Eczacıları Birlig i-is then responsible for importing the drug, and the cost is directly covered by the SGK's reimbursement scheme, with price margins updated every 6 months [20] . This illustrates that there are both licensed and unlicensed orphan drugs on the Turkish market and that all orphan drugs are covered by a reimbursement scheme, whether licensed or not. The aim of this study was to shed light on the use of orphan drugs in Turkey to aid further classifications of rare diseases and assessments of orphan drugs in the country.
Methods
The study included orphan drugs recognized by the EU and published by the EMA. A detailed search of the PubMed database for articles published before 2012 was conducted. The following key words were used: "orphan medicines" and "Turkey," "orphan drugs" and "Turkey," "orphan drug" and "Turkey," and "orphan drug market" and "Turkey." Eight relevant published articles were found, none of which was related to the Turkish orphan medicines market.
Results
Of 60 different orphan drugs defined by the EMA, 50 entered the Turkish market in recent years. Half of these were authorized. The remaining drugs (preauthorization phase) were imported. All the drugs are fully reimbursed at present.
In 2008, there were 14 authorized and 19 nonauthorized orphan drugs on the market. In 2010, there were 18 authorized and 17 nonauthorized orphan drugs ( Table 1) . As an example, lenalidomide, which was not authorized in 2009, was placed on the market in 2010. Its total market value increased from €148 million to €208 million between 2008 and 2010. There was a similar peak in units. Between 2008 and 2010, the units and value of all nonauthorized drugs increased more than those of authorized drugs (234% and 43%, respectively, and 71% and 24%, respectively) ( Table 2 and Fig. 2) .
The average cost per unit was €1187 in 2008. It decreased to €1002 in 2011. The reduction in the average unit cost was caused by a decrease in the average unit cost of authorized orphan medicines from €1137 to €878 in the 3 years. The decrease was approximately 22%. The average unit price of unauthorized orphan medicines, however, rose from €1885 to €1894 in the 3 years. In parallel, the difference between the average unit cost of authorized and unauthorized medicines increased from €747 to €1016 in this period. The ratio between the average unit cost of authorized and unauthorized medicines rose from 1.65 to 2.15. In other words, the average unit cost of unauthorized orphan medicines was 65% and 115% greater than the average unit cost of authorized orphan medicines in 2008 and 2011, respectively. Antineoplastic agents accounted for the highest percentage of orphan drugs. In 2010, 18 antineoplastic agents had 58% share of the total orphan drug market, at a value of €120 million. These were followed by alimentary tract and metabolism medicines (Table 3) . Darasirox had the highest unit percentage among the authorized medicines, but imatinib had the highest value. Among all unauthorized medicines, galsulfase had the highest unit and market share. In addition, five authorized and unauthorized orphan drugs shared 78% and 86% of the total orphan drug market, respectively (Tables 4 and 5) .
Interesting findings were obtained for lenalidomide, which was an unauthorized drug. Lenalidomide was imported in the preauthorization phase in 2009 (409 units consumed) through to the first 
quarter of 2010 (207 units consumed). Easy access of the patient population to this orphan drug was ensured in the preauthorization phase, and sales of lenalidomide rose to 866 units in the remaining three quarters of 2010. Thus, sales of the drug could be 1154 units if we extrapolate the three-quarter sales to 1 year with the estimation. Moreover, the price for reimbursement changed within these years. In 2009, when it was available through the easy access procedure, the reimbursement price of lenalidomide was €5301 to €6448, depending on the package size. After the drug was launched in 2010, the price fell to €3920 to €4523 because of reimbursement discounts. The total unit sales of lenalidomide, however, increased by 180%, and its total market value rose by 70% following the decreased reimbursement price after the launch. According to IMS data, the total market value of reimbursed medicines increased from €6.6 billion to €7.4 billion from 2008 to 2010. The market share of orphan drugs of the total market increased from 2% to 3%, a rise of nearly 50%, the highest increase among all medicinal product categories.
It is noted that there are 1268 different molecules in the positive list for reimbursement (€7.4 billion) according to the SGK positive list. Based on these data, the average market value of the molecules was calculated as €5.8 million each for 2010. However, the average market value of orphan molecules was calculated as €7.5 million for 2010.
Conclusions and Discussion
The findings of this study provide unique information on the orphan drug market in Turkey. Based on the literature search, to the best of our knowledge, this is the first study examining the economic impact of orphan drugs on Turkey. The current findings should be of use to private and public stakeholders responsible for decision making relating to Turkey's orphan drug market.
Similar to regulatory and reimbursement procedures, market access procedures for orphan drugs are more complex than those for conventional drugs. Although the United States and the EU have defined rare diseases and orphan drugs, the definitions are not the same. Different definitions may affect all market access schemes in the United States and the EU and cause disagreements between stakeholders. Nevertheless, it is better to have some sort of definition than no definition.
Orphan drug regulations have been in force in the EU for more than 10 years. The average market share of orphan drugs in the EU was cited recently as 2% to 3% [21] , making it the same as in Turkey. The budget impact of all orphan drugs was mostly lower than that of common drugs, whereas the average budget impact of orphan molecules was higher than that of conventional molecules. Today, 50 molecules are available for patients with rare diseases in Turkey, with a market share of approximately 3% [22] . The market share, however, may increase in coming years with the prospective launch of new orphan drugs because the average orphan molecule market value is 30% higher than that of the average market value of conventional drug molecules.
The value of Turkey's orphan drug market increased by 40% between 2008 and 2010. In the same given time, the consumption of total orphan drug units increased by 82%. The difference between the units and market value in these years might be due to public price cuts, with mandatory discount rates increasing from 20.5% to 32.5% between 2008 and 2010. In addition, reference prices might have changed. However, the average unit cost for authorized orphan drugs decreased in the 3 years, whereas the average unit cost of unauthorized orphan drugs increased. The former may be the result of changes in reference prices and reimbursement discounts. Unlike authorized drugs, unauthorized orphan drugs are imported and not subject to reference pricing and reimbursement discounts by the Türk Eczacıları Birliği. A detailed analysis could shed light on the source of differences between the average unit cost of authorized and unauthorized orphan drugs.
As noted earlier, the TITCK governs access to unauthorized orphan drugs in Turkey, and patients considered to be in dire need have access to unauthorized drugs under existing regulations for unauthorized human medicinal products. The total sales of orphan drugs may be boosted after licensing these products, as seen in the case of lenalidomide, for which total unit sales increased by 180% following its launch in Turkey. The source of this increase is unclear. It also remains unclear whether patients who need lenalidomide actually have access to the drug. The increase in the total unit sales of lenalidomide after its launch may be due to stringent scientific and technical evaluations by the TITCK earlier and the removal of these after licensing of the drug. The authorized drug reimbursement process likely also enhanced patient access to the drug. Against all odds, this discrepancy is in need of further assessment.
Although orphan drug legislation is not yet established in Turkey, pricing and reimbursement policies for this particular group of drugs are already in place. As noted in an earlier study, incentives to develop orphan drugs do not yet exist in Turkey; however, procedures are in place to facilitate access to orphan drugs [22] . As a result, patients can access treatment in a rapid and equitable manner [22] . This study facilitates additional analyses of orphan drug prices and reimbursement in Turkey. Further evaluation of prices of authorized and unauthorized orphan drugs could be carried out on a case-by-case basis. The latter would shed light on the diverse pricing and reimbursement policies of countries worldwide. 
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